Morgan Stanley Sticks to Its Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)Tip Ranks·5 hours ago03692-1.30%
Key facts: GSK Q2 revenue up 5%, £1.9B savings target; ris-rez PFS metTradingView·1 day ago, 02:15 AMGSK-2.16%03692-1.30%
GSK’s partner posts positive osteosarcoma data for B7-H3 drug, bolstering oncology pushTip Ranks·2 days ago, 05:12 AMGSK-2.16%03692-1.30%
REG - GSK PLC - Hansoh positive 2nd Phase III results for Riz-RezLondon Stock Exchange·2 days ago, 05:06 AMGSK-2.16%03692-1.30%
Hansoh Pharma says Artemis-011 Phase 3 trial of HS-20093 meets primary PFS endpoint in osteosarcomaPUBT·2 days ago, 05:01 AM03692-1.30%
Nomura Expects HANSOH PHARMA Interim Profit Dragged by R&D Expenses; Cuts TP to HKD37.24AASTOCKS News·Jul 27 at 01:52 AM03692-1.30%
CLSA Raises HANSOH PHARMA TP to HKD42, Expects Multiple New Drug Launches Next Yr to Support Earnings GrowthAASTOCKS News·Jul 26 at 10:14 PM03692-1.30%
Hong Kong Mid-Caps Drive Summer Dealmaking Amid USD 2.3 Billion Bio-Licensing and Stock BuybacksGlobal Report·Jul 22 at 04:18 AM03692-1.30%01187-1.60%
Hansoh Pharmaceutical Group Company Limited (3692) Gets a Buy from Morgan StanleyTip Ranks·Jul 15 at 08:55 PM03692-1.30%
Hansoh-backed Avere agrees to merge with NextCure in all-stock dealPUBT·Jul 14 at 05:01 AM03692-1.30%NXTC+0.20%
